secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021241
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex Q1 2023 revenue $13.7M (+2% YoY), net loss narrows to $2.1M
------------------------------------------------------------------

- Cyclo G6 revenue $3.7M (+4% YoY); 61 systems sold vs 56 a year ago.
- Retina product revenue flat at $7.2M; gross margin fell to 43.3% from 44.6%.
- Net loss of $2.1M ($0.13/sh) vs $2.4M ($0.15/sh); cash $11.0M.
- FY2023 guidance reaffirmed: revenue $57-59M, Cyclo G6 probes 65k-67k.
- FDA clearance received in February for new single-spot 532/577 laser platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000095017023021241/0000950170-23-021241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000095017023021241/irix-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer